Amytrx Therapeutics

Amytrx is a clinical-stage biopharmaceutical company advancing the next generation of new anti-inflammatory peptide therapies for patients suffering from chronic inflammatory diseases. The company is a group of dedicated scientific, medical, and business professionals all deeply committed to positively transforming the health and lives of patients.... The company's breakthrough therapeutic platform, AMTX-100, is a first-in-class anti-inflammatory peptide bioengineered from human protein sequences that modulate the immune system by a natural process, reducing pathogenesis in a range of conditions. This completely novel approach to restoring immune balance harnesses significant potential for safer and more effective treatments across a range of diseases where medical need remains. The company's business strategy includes exploring collaborative opportunities with pharmaceutical and biotechnology partners, as well as clinical and research organizations, to advance new or complementary therapies for chronic diseases where excessive inflammation or metabolic imbalances play key causative roles.Read More